Seres Therapeutics Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Seres Therapeutics stock.
View analyst ratings for Seres Therapeutics or view top-rated stocks.

Wall Street analysts have given Seres Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Seres Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Seres Therapeutics.

Seres Therapeutics, Inc. (NASDAQ:MCRB) announced its quarterly earnings data on Tuesday, August, 3rd. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.12. The biotechnology company earned $5.26 million during the quarter, compared to the consensus estimate of $4.40 million. Seres Therapeutics had a negative trailing twelve-month return on equity of 87.12% and a negative net margin of 441.65%.
View Seres Therapeutics' earnings history.

Seres Therapeutics' stock was trading at $2.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MCRB stock has increased by 161.7% and is now trading at $6.91.
View which stocks have been most impacted by COVID-19.

7 brokers have issued 1 year price objectives for Seres Therapeutics' stock. Their forecasts range from $7.00 to $32.00. On average, they anticipate Seres Therapeutics' stock price to reach $20.83 in the next year. This suggests a possible upside of 201.5% from the stock's current price.
View analysts' price targets for Seres Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Seres Therapeutics include ATA (ATAI), Verve Therapeutics (VERV), Taro Pharmaceutical Industries (TARO), IGM Biosciences (IGMS), Atea Pharmaceuticals (AVIR), Corcept Therapeutics (CORT), Ligand Pharmaceuticals (LGND), Morphic (MORF), Harmony Biosciences (HRMY), Organogenesis (ORGO), Indivior (INVVY), Cassava Sciences (SAVA), Rocket Pharmaceuticals (RCKT), Ironwood Pharmaceuticals (IRWD) and Nuvation Bio (NUVB).
View all of MCRB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), The Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Seres Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Flagship Pioneering Inc. (15.68%), FMR LLC (14.09%), ARK Investment Management LLC (10.59%), BlackRock Inc. (7.00%), Sumitomo Mitsui Trust Holdings Inc. (5.77%) and Nikko Asset Management Americas Inc. (5.76%).
View institutional ownership trends for Seres Therapeutics.

MCRB stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Federated Hermes Inc., Flagship Pioneering Inc., Goldman Sachs Group Inc., Squarepoint Ops LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for Seres Therapeutics or view top insider-selling stocks.

MCRB stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., FMR LLC, Morgan Stanley, Morgan Stanley, BlackRock Inc., Lord Abbett & CO. LLC, Integral Health Asset Management LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Seres Therapeutics or or view top insider-buying stocks.

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MCRB stock can currently be purchased for approximately $6.91.

Seres Therapeutics has a market capitalization of $633.78 million and generates $33.22 million in revenue each year. The biotechnology company earns $-89,130,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

Seres Therapeutics employs 155 workers across the globe.

The official website for Seres Therapeutics is www.serestherapeutics.com.

Seres Therapeutics is headquartered at 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139.

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (617) 945-9626 or via email at [email protected].